Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA, Philadelphia, PA and Oxford, England, with manufacturing facilities in Ireland and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence.
Together, we are more than 3,100 experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to market.
For more information, please see our website at www.jazzpharma.com and follow us on Twitter at @JazzPharma. For information on fraudulent schemes involving our company name and recruitment, please visit https://bit.ly/2J1EjMA. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.
Location: Ireland, Dublin
Employees: 1001-5000
Total raised: $179M
Founded date: 2003
Investors 7
Funding Rounds 1
Date | Series | Amount | Investors |
17.05.2007 | IPO | $179M | - |
Mentions in press and media 26
Date | Title | Description | Source |
24.04.2024 | DATAcc by DiMe Launches Core Measures for Sleep | Core sleep measures and resources will help transform sleep research and care to advance the treatme... | salamancap... |
07.04.2022 | NASDAQ Roundtable: $JAZZ signs Agreement with $HOWL Today: I... | $AVCO Therapeutics to fight Cancer AVCO Rings NASDAQ Bell Werewolf Therapeutics logo Werewolf Therap... | einpresswi... |
10.01.2022 | Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustai... | DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its Vi... | marketscre... |
15.12.2021 | Jazz Pharmaceuticals Announces First Patient Enrolled in Pha... | DUBLIN, Dec. 15, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that t... | marketscre... |
03.08.2021 | Jazz Pharmaceuticals : Announces Second Quarter 2021 Financi... | DUBLIN, Aug. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financi... | marketscre... |
13.07.2021 | Jazz Pharmaceuticals : Announces Rylaze™ (asparaginase erwin... | DUBLIN, July 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that t... | marketscre... |
30.06.2021 | Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ ... | prnewswire... | |
17.06.2021 | JAZZ PHARMACEUTICALS PLC Jazz Pharmaceuticals : Updates 202... | DUBLIN, June 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today updated its full... | marketscre... |
09.06.2021 | JAZZ PHARMACEUTICALS PLC Jazz Pharmaceuticals : Presents 18... | DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13... | marketscre... |
05.05.2021 | GW PHARMACEUTICALS PLC GW Pharmaceuticals : Jazz Pharmaceut... | DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completi... | marketscre... |
Show more